Phase II/III Veliparib or Placebo With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma
Glioblastoma · Gliosarcoma
Enrolment: 447 · Results not recorded
Loading the evidence…
Drug · PARP 1, 2 and 3 inhibitor (INHIBITOR, direct interaction, disease efficacy true; mec_id 5662)
2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Glioblastoma · Gliosarcoma
Enrolment: 447 · Results not recorded
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Enrolment: 66 · Results not recorded
Ovarian Cancer · Triple-Negative Breast Cancer · Fallopian Tube Cancer
Enrolment: 124 · Results not recorded
Ovarian Carcinoma · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Enrolment: 431 · Results not recorded
Advanced Malignant Solid Neoplasm
Enrolment: 121 · Results not recorded
Advanced Malignant Solid Neoplasm · Triple-Negative Breast Carcinoma
Enrolment: 73 · Results not recorded
Gastric Cancer
Enrolment: 60 · Results not recorded
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Enrolment: 12 · Results not recorded
Neoplasms
Enrolment: 0 · Results not recorded
Solid Tumors With BRCA/BARD/PALB Mutations · Triple Negative Breast Cancer · High Grade Serous Ovarian Cancer
Enrolment not recorded · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Intrastriatal needle track injury and intrastriatal injection of the alarmin S100B (striatal coordinates 1.0 mm anterior, 1.9 mm lateral, 3.5 mm deep relative to bregma)
S100B induced microglial process retraction, soma enlargement, upregulation of IL-1beta, TNF-alpha and iNOS, and release of MMP9 (about 2-fold) and nitric oxide (about 10-fold). Most of these effects were attenuated in PARP-1 knockout microglia and by veliparib, although MMP9 and nitric oxide relea…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.